These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 32742927)
1. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. Narayanan R Asian J Urol; 2020 Jul; 7(3):271-283. PubMed ID: 32742927 [TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
3. AR Structural Variants and Prostate Cancer. Cato L; Shomali M Adv Exp Med Biol; 2022; 1390():195-211. PubMed ID: 36107320 [TBL] [Abstract][Full Text] [Related]
4. Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer. Khan F; Anelo OM; Sadiq Q; Effah W; Price G; Johnson DL; Ponnusamy S; Grimes B; Morrison ML; Fowke JH; Hayes DN; Narayanan R Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979627 [TBL] [Abstract][Full Text] [Related]
5. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer. Case TC; Merkel A; Ramirez-Solano M; Liu Q; Sterling JA; Jin R Transl Oncol; 2021 Nov; 14(11):101213. PubMed ID: 34461557 [TBL] [Abstract][Full Text] [Related]
6. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195 [TBL] [Abstract][Full Text] [Related]
7. Role of Androgen Receptor in Prostate Cancer: A Review. Fujita K; Nonomura N World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899 [TBL] [Abstract][Full Text] [Related]
8. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864 [TBL] [Abstract][Full Text] [Related]
9. An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. Imamura Y; Tien AH; Pan J; Leung JK; Banuelos CA; Jian K; Wang J; Mawji NR; Fernandez JG; Lin KS; Andersen RJ; Sadar MD JCI Insight; 2016 Jul; 1(11):. PubMed ID: 27525313 [TBL] [Abstract][Full Text] [Related]
10. Decoding the androgen receptor splice variants. Lu C; Luo J Transl Androl Urol; 2013 Sep; 2(3):178-186. PubMed ID: 25356377 [TBL] [Abstract][Full Text] [Related]
11. The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy. Messner EA; Steele TM; Tsamouri MM; Hejazi N; Gao AC; Mudryj M; Ghosh PM Biomedicines; 2020 Oct; 8(10):. PubMed ID: 33076388 [TBL] [Abstract][Full Text] [Related]
12. Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Leung JK; Sadar MD Front Endocrinol (Lausanne); 2017; 8():2. PubMed ID: 28144231 [TBL] [Abstract][Full Text] [Related]
13. BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer. Lee II; Kuznik NC; Rottenberg JT; Brown M; Cato ACB J Mol Endocrinol; 2019 May; 62(4):R289-R299. PubMed ID: 30913537 [TBL] [Abstract][Full Text] [Related]
14. Regulation of androgen receptor variants in prostate cancer. Zhu Y; Luo J Asian J Urol; 2020 Jul; 7(3):251-257. PubMed ID: 33024700 [TBL] [Abstract][Full Text] [Related]
15. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Shiota M; Yokomizo A; Fujimoto N; Naito S Curr Cancer Drug Targets; 2011 Sep; 11(7):870-81. PubMed ID: 21762076 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival. Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471 [TBL] [Abstract][Full Text] [Related]
18. Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges. Kita Y; Goto T; Akamatsu S; Yamasaki T; Inoue T; Ogawa O; Kobayashi T Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30248934 [TBL] [Abstract][Full Text] [Related]
19. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer. Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197 [TBL] [Abstract][Full Text] [Related]
20. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]